ClinicalTrials.gg

Program

PARP1 Inhibitor HRS-1167

Also written as “M9466”, “HRS-1167 tablets” and “HRS-1167”.

Its studies are mostly in Ovarian Neoplasms · Prostatic Neoplasms, led by 2 companies.

Furthest: phase 2, since Feb 26, 20246 company-led studies, 4 open or runningNext primary completion: Dec 31, 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Jiangsu HengRui Medicine33 open or runningphase 2since Feb 26, 2024Jul 13, 2022Dec 31, 2026phase 1 · NCT05473624
Merck KGaA, Darmstadt, Germany31 open or runningphase 1since May 14, 2024May 14, 2024Feb 22, 2027phase 1 · NCT06421935

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 13, 2022First study: phase 1 study in Advanced Solid TumorsNew to Jiangsu HengRui MedicineJiangsu HengRui Medicine · NCT05473624 · 153 planned · China
  2. Feb 26, 2024Phase 2 study in Ovarian NeoplasmsJiangsu HengRui Medicine · NCT06308406 · 54 planned · China
  3. May 14, 2024Merck KGaA, Darmstadt, Germany’s first study: phase 1 study in Ovarian NeoplasmsNew to Merck KGaA, Darmstadt, GermanyMerck KGaA, Darmstadt, Germany · NCT06421935 · 60 enrolled · United States, Australia, Japan and more
  4. Jul 15, 2024Phase 1 study in Advanced Solid TumorMerck KGaA, Darmstadt, Germany · NCT06509906 · 3 enrolled · United States, Australia, Japan and more
  5. Nov 12, 2024Phase 2 study in Prostatic NeoplasmsJiangsu HengRui Medicine · NCT06689163 · 66 planned · China
  6. Dec 2, 2024Phase 1 study in Advanced Solid TumorsMerck KGaA, Darmstadt, Germany · NCT06719973

Ahead

  1. Dec 31, 2026Primary completion: phase 1 study in Advanced Solid TumorsJiangsu HengRui Medicine · NCT05473624
  2. Feb 22, 2027Primary completion: phase 1 study in Ovarian NeoplasmsMerck KGaA, Darmstadt, Germany · NCT06421935

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 6 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT06719973Advanced Solid Tumors1WithdrawnMerck KGaA, Darmstadt, GermanyMay 14, 20250
NCT06689163Prostatic Neoplasms · China2RecruitingJiangsu HengRui MedicineNov 30, 202566
NCT06509906Advanced Solid Tumor · United States, Australia, Japan and more1TerminatedMerck KGaA, Darmstadt, GermanyDec 2, 20253
NCT06421935Ovarian Neoplasms · United States, Australia, Japan and more1Active, not recruitingMerck KGaA, Darmstadt, GermanyFeb 22, 202760
NCT06308406Ovarian Neoplasms · China2RecruitingJiangsu HengRui MedicineOct 202554
NCT05473624Advanced Solid Tumors · China1RecruitingJiangsu HengRui MedicineDec 31, 2026153

How it is read

Names in the registry

  • “M9466”, 3 entries
  • “HRS-1167 tablets”, 1 entry
  • “HRS-1167”, 1 entry
  • “Bevacizumab; HRS-1167”, 1 entry

Codes read as this program: HRS1167.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.